ChemoCentryx receives FDA orphan products development grant
ChemoCentryx announced the FDA has awarded the Company a one-year grant of $500,000 to assist in the clinical development of CCX168, the Company's lead drug candidate for treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. April 28, 2016